GotoPER - Physicians' Education Resource
Free CE/CMEAdaptive Learning

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Create AccountAlready Registered? Login Here

Release Date

July 31, 2026

Expiration Date

August 1, 2027

Credits

1.5 CME

Activity Overview

Welcome to this OncoByte Adaptive Learning Pathway!

Each OncoByte video features a 5-minute presentation by our expert faculty on a key foundational topic related to the use of TROP2-targeting antibody-drug conjugates (ADCs) in the treatment of non–small cell lung cancer (NSCLC). Prior to watching an OncoByte, you will be asked a question on the topic to assess your baseline knowledge and confidence. If you answer the question correctly and confidently, you will continue to the next topic. If you answer the question incorrectly or without high confidence, you will continue to the OncoByte video.

After proceeding through your customized learning pathway, you will be led to panel discussions. Our expert faculty will help you synthesize the latest information and data on the safety and efficacy of TROP2-targeting ADCs in patients with NSCLC.

Target Audience

This educational activity is directed toward a global audience of oncology clinicians, including medical oncologists, thoracic oncologists, pulmonologists, advanced practice providers, oncology nurses, pharmacists, and other members of the multidisciplinary cancer care team involved in the management of patients with NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess recent clinical trial and emerging pipeline data for TROP2-targeted ADCs and combination strategies in NSCLC
  • Select evidence-informed treatment and sequencing strategies for patients with NSCLC across relevant biomarker subsets
  • Evaluate appropriate interpretation of exploratory CNS activity signals for TROP2-targeted ADCs
  • Implement multidisciplinary strategies to monitor, mitigate, and manage high-impact toxicities associated with TROP2-targeted ADCs
Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

PER is proud to partner with European Thoracic Oncology Platform.

Follow Us on Social Media!

You Also Might Like...

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of TreatmentFree CE/CME

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®Free CE/CME

27th Annual International Lung Cancer Congress®

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC CareVirtual Event

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing CareFree CE/CME

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Course

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Create Account